Precision Nanomedicines for Cancer Detection and Treatment

Precision Nanomedicines for Cancer Detection and Treatment

September 27, 2017


727 E. Tyler St.
Tempe, AZ 85287


Biodesign Institute, Auditorium

Date and Time

October 10, 2017, 11:00 am (Length: 1 hour 0 minutes)

iCal Download

Daniel Heller, Ph.D., Head of Cancer Nanomedicine Laboratory, Assistant Member, Memorial Sloan Kettering Cancer Center, Assistant Professor, Weill Cornell Medical College, Cornell University

Metastatic tumors are responsible for the vast majority of cancer deaths. Such tumors are often poorly accessible to nanoscale drug delivery systems because of the vascular barrier, which often prevents the targeting of the tumor site. Heller is investigating new targets to localize precision drugs, such as kinase inhibitors, to the metastatic tumor microenvironment. His team is developing implantable nanosensors, using the unique optical properties of carbon nanotubes, to facilitate noninvasive detection, via optical detection through living tissues. The sensors could enable early detection of cancer in people at high risk for the disease in successfully treated patients to monitor recurrence, or in patients who are undergoing treatment to inform clinical decisions.